AIMS: The Fas-associated death domain gene (FADD) is often overexpressed in squamous cell carcinoma of the head and neck (HNSCC), and is considered to be a driver gene in amplification of the chromosomal 11q13.3 region. Amplification of 11q13.3 is associated with increased metastasis in HNSCC and breast cancer. The aim of this study was to investigate the association between FADD protein expression in advanced-stage HNSCC and clinicopathological features and outcome. METHODS AND RESULTS: Tumour tissues of 177 HNSCC patients uniformly treated with primary surgery and postoperative radiotherapy were collected. FADD expression was assessed on pretreatment tumour biopsies using immunohistochemistry. High FADD expression was detected in 44% of the HNSCC patients. High expression was associated with an increased rate of lymph node metastasis (P = 0.001) and with a shorter distant metastasis-free interval (DMFI) (HR 2.6, 95% CI 1.0-6.7, P = 0.046) when lymph node metastases were present. CONCLUSIONS: Our data show that an increase in FADD expression is associated with a higher incidence of lymph node metastasis at presentation, and with shorter DMFI when lymph node metastases are present. High FADD expression in the primary tumour could be a useful marker to select patients for systemic treatment strategies that reduce the risk of distant metastases.
AIMS: The Fas-associated death domain gene (FADD) is often overexpressed in squamous cell carcinoma of the head and neck (HNSCC), and is considered to be a driver gene in amplification of the chromosomal 11q13.3 region. Amplification of 11q13.3 is associated with increased metastasis in HNSCC and breast cancer. The aim of this study was to investigate the association between FADD protein expression in advanced-stage HNSCC and clinicopathological features and outcome. METHODS AND RESULTS:Tumour tissues of 177 HNSCC patients uniformly treated with primary surgery and postoperative radiotherapy were collected. FADD expression was assessed on pretreatment tumour biopsies using immunohistochemistry. High FADD expression was detected in 44% of the HNSCC patients. High expression was associated with an increased rate of lymph node metastasis (P = 0.001) and with a shorter distant metastasis-free interval (DMFI) (HR 2.6, 95% CI 1.0-6.7, P = 0.046) when lymph node metastases were present. CONCLUSIONS: Our data show that an increase in FADD expression is associated with a higher incidence of lymph node metastasis at presentation, and with shorter DMFI when lymph node metastases are present. High FADD expression in the primary tumour could be a useful marker to select patients for systemic treatment strategies that reduce the risk of distant metastases.
Authors: Krzysztof Szyfter; Malgorzata Wierzbicka; Jennifer L Hunt; Alessandra Rinaldo; Juan P Rodrigo; Robert P Takes; Alfio Ferlito Journal: Eur Arch Otorhinolaryngol Date: 2014-10-30 Impact factor: 2.503
Authors: Danielle F Eytan; Grace E Snow; Sophie Carlson; Adeeb Derakhshan; Anthony Saleh; Stephen Schiltz; Hui Cheng; Suresh Mohan; Shaleeka Cornelius; Jamie Coupar; Anastasia L Sowers; Lidia Hernandez; James B Mitchell; Christina M Annunziata; Zhong Chen; Carter Van Waes Journal: Cancer Res Date: 2016-07-28 Impact factor: 12.701
Authors: Cristina García-Inclán; Alejandro López-Hernández; Marta Alonso-Guervós; Eva Allonca; Sira Potes; Santiago Melón; Fernando López; José Luis Llorente; Mario Hermsen Journal: Sci Rep Date: 2014-05-12 Impact factor: 4.379
Authors: Eun Ji Choi; Jeong A Yun; Sahrish Jabeen; Eun Kyoung Jeon; Hye Sung Won; Yoon Ho Ko; Su Young Kim Journal: World J Surg Oncol Date: 2014-05-01 Impact factor: 2.754